ResearcherWakayama Medical UniversityNo recent work listed
Masahiro Katsuda
Matched on OpenAlex author ID A5053066818. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 5
- Advances in immunotherapy for pancreatic ductal adenocarcinoma. First author DOI 10.1002/jhbp.944↗
- A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
- Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. First author DOI 10.1002/ijc.30510↗
- [Present and future status of therapeutic cancer peptide vaccine therapy for patients with pancreatic cancer]. Co-author PMID 25857063↗
- Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Co-author DOI 10.1016/j.canlet.2011.02.013↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hiroki Yamaue · 5 shared papers, 2011–2021 · strength 0.41
- Paper Advances in immunotherapy for pancreatic ductal adenocarcinoma. DOI 10.1002/jhbp.944↗
- Paper [Present and future status of therapeutic cancer peptide vaccine therapy for patients with pancreatic cancer]. PMID 25857063↗
- Paper A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine load… DOI 10.1186/s13063-019-3332-5↗
- Motoki Miyazawa · 4 shared papers, 2011–2021 · strength 0.31
- Paper Advances in immunotherapy for pancreatic ductal adenocarcinoma. DOI 10.1002/jhbp.944↗
- Paper A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine load… DOI 10.1186/s13063-019-3332-5↗
- Paper Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resec… DOI 10.1002/ijc.30510↗
- Seiko Hirono · 2 shared papers, 2017–2021 · strength 0.21
- Manabu Kawai · 2 shared papers, 2017–2021 · strength 0.21
- Yuji Kitahata · 1 shared paper, 2021 · strength 0.15
- Ken‐ichi Okada · 1 shared paper, 2021 · strength 0.15
- Akio Katanuma · 2 shared papers, 2017–2019 · strength 0.13
- Paper A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine load… DOI 10.1186/s13063-019-3332-5↗
- Paper Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resec… DOI 10.1002/ijc.30510↗
- Shingo Asahara · 1 shared paper, 2019 · strength 0.07
- Hiroaki Nagano · 1 shared paper, 2019 · strength 0.07
- Kentaro Sudo · 1 shared paper, 2019 · strength 0.07
- Kenichi Hakamada · 1 shared paper, 2019 · strength 0.07
- Sohei Satoi · 1 shared paper, 2019 · strength 0.07
- Suguru Yamada · 1 shared paper, 2019 · strength 0.07
- Tatsuya Ioka · 1 shared paper, 2019 · strength 0.07
- Masayuki Furukawa · 1 shared paper, 2019 · strength 0.07
- Kazuo Hara · 1 shared paper, 2019 · strength 0.07
- Takahiro Akahori · 1 shared paper, 2019 · strength 0.07
- Masaichi Ohira · 1 shared paper, 2019 · strength 0.07
- Makoto Ueno · 1 shared paper, 2019 · strength 0.07
- Tsutomu Fujii · 1 shared paper, 2019 · strength 0.07
- Masayuki Kitano · 1 shared paper, 2019 · strength 0.07
- Itaru Endo · 1 shared paper, 2019 · strength 0.07
- Hiroshi Ishii · 1 shared paper, 2017 · strength 0.06
- Masato Ozaka · 1 shared paper, 2017 · strength 0.06
- Ken‐ichi Okada · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.